Related Experiment Video

Updated: Jul 4, 2026

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Daily salbutamol in young patients with SMA type II

Marika Pane1, Susanna Staccioli, Sonia Messina

  • 1Department of Paediatric Neurology, Catholic University, Policlinico Gemelli Largo Gemelli, 00168 Rome, Italy.

Neuromuscular Disorders : NMD
|June 27, 2008
PubMed

Insights

This pilot study suggests salbutamol (albuterol) may improve motor function in young children with spinal muscular atrophy (SMA) type II. The drug was well-tolerated, showing potential benefits for SMA patients.

Area of Science:

  • Neurology
  • Pediatrics
  • Pharmacology

Background:

  • Spinal Muscular Atrophy (SMA) type II is a severe neuromuscular disorder affecting motor function in children.
  • Current treatments for SMA focus on disease modification, with limited options for symptomatic relief of motor deficits.
  • Salbutamol (albuterol), a beta-2 adrenergic agonist, is known for its bronchodilator effects but has been explored for other muscle-related conditions.

Purpose of the Study:

  • To evaluate the tolerability and clinical response of salbutamol in young children diagnosed with SMA type II.
  • To assess the safety profile of long-term salbutamol administration in this pediatric population.
  • To determine if salbutamol can lead to measurable improvements in motor function in children with SMA type II.

Main Methods:

  • An open pilot study involving 23 children aged 30 months to 6 years with SMA type II.
  • Participants received salbutamol (2 mg, three times daily) for a duration of 1 year.
  • Motor function was longitudinally assessed using the Hammersmith Motor Functional Scale at baseline and at 6 and 12 months during treatment.

Main Results:

  • No significant functional decline was observed between the pre-treatment assessment (T0) and baseline (T1).
  • A statistically significant improvement in motor function scores was recorded at 6 and 12 months of salbutamol treatment compared to baseline (p=0.006).
  • Salbutamol was generally well-tolerated, with no major reported side effects during the study period.

Conclusions:

  • Salbutamol demonstrates potential as a beneficial therapeutic agent for improving motor function in pediatric SMA type II patients.
  • The drug exhibits a favorable tolerability profile in this cohort, suggesting a good safety margin.
  • Further investigation through larger, randomized, double-blind, placebo-controlled trials is warranted to validate these promising preliminary findings.

More Related Videos

Conducting Respiratory Oscillometry in an Outpatient Setting14:49

Conducting Respiratory Oscillometry in an Outpatient Setting

Published on: April 8, 2022

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...